Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Oct;23(3):163-9.
doi: 10.1016/s0740-5472(02)00244-1.

Heroin detoxification with buprenorphine on an inpatient psychiatric unit

Affiliations
Clinical Trial

Heroin detoxification with buprenorphine on an inpatient psychiatric unit

Bethany A DiPaula et al. J Subst Abuse Treat. 2002 Oct.

Abstract

The purpose of this open-label, uncontrolled study was to evaluate the feasibility of administering off-label buprenorphine in combination with ancillary medications for inpatient short-term detoxification of heroin-dependent patients at a psychiatric facility. A sample of 20 heroin-dependent patients admitted to an urban psychiatric hospital was administered buprenorphine 6, 4, and 2 mg/day during the first, second, and third day of detoxification, respectively, and then observed during the fourth and fifth day. Eighty-five percent of the subjects abused other substances, 75% reported cocaine abuse/dependence, 75% had comorbid mood disorders. All subjects completed the medication phase of the study. No clinically significant adverse events were reported. There was a significant decrease in the Clinical Investigation Narcotic Assessment (CINA) total score between baseline and days 2 through 5. The results suggest that buprenorphine is well tolerated and may be beneficial for medically supervised short-term withdrawal from heroin for hospitalized psychiatric patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean (SE) CINA scores for all patients completing the 3-day buprenorphine detoxification (n = 20).

Similar articles

Cited by

References

    1. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphinenaloxone tablet. Drug and Alcohol Dependence. 2000;58:143–152. - PubMed
    1. Blennow G, Fergusson A, Medvedeo A. Buprenorphine as a new alternative for detoxification of heroin addicts. Laekartidningen. 2000;97:1830–1833. - PubMed
    1. Brooner RK, King VL, Kidorf M, Schmidt CW, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry. 1997;54(1):71–80. - PubMed
    1. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence. 1994;36:115–121. - PubMed
    1. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research. 1999;35(Suppl):93–100. - PubMed

Publication types